In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $150.0 for Novo Nordisk over the last 3 months.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Looking at options history for Novo Nordisk NVO we detected 8 trades. If we consider the specifics of each trade, it is ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Private equity-backed Infinity Natural Resources raised $265 million on Thursday in its initial public offering in the U.S., the latest first-time share sale by an energy company in New York in recent ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.